• Home

Clinical trials - page 15

Essais cliniques
Search for a clinical trial
Filter

183 result(s)

  • Paris, Saint-Cloud
    POP-ART
    A Phase I Study on Tuvusertib (oral ATR inhibitor) in Combination with PLX038 (Topo1 inhibitor) with dose expansion cohorts in patients;with advanced solid tumors.

    FRANCOIS-CLEMENT BIDARD

  • Childhood and adolescent cancers
    Paris
    Selupass
    Post-Authorisation Safety Study of Paediatric Patients Initiating Selumetinib: A Multiple-Country Prospective Cohort Study

    ISABELLE AERTS GAJDOS

  • Breast cancer
    Paris
    MK-2870-010
    An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent;and in Combination with Pembrolizumab Versus Treatment of PhysicianÀs Choice in;Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

    DELPHINE LOIRAT

  • Paris
    EGL-001 (EGL-121)
    First-in-human Trial of EGL-001 in Patients with Selected Advanced And/·or Metastatic Solid Tumors

    CHRISTOPHE LE TOURNEAU

  • Childhood and adolescent cancers
    Paris
    I3Y-MC-JPEH
    A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

    ISABELLE AERTS GAJDOS

  • ENT/Head and Neck Cancers
    Paris, Saint-Cloud
    SURVEILLE HPV
    National, multicentre, open-label, randomised, phase II study evaluating HPV circulating DNA as biomarker to detect the recurrence, in order to improve post therapeutic surveillance of HPV-driven oropharyngeal cancers.

    JOEY MARTIN

  • Sarcomas
    Paris
    TRUST
    Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma (TRUST)

    CLEMENT BONNET

  • Paris
    TUMOSS
    Comparative Evaluation of Care Strategies on Dressing Change-induced Bleeding in Patients With Bleeding Malignant Wounds (TUMOSS)

  • Breast cancer
    Paris
    BGB-43395-101
    Phase Ia/Ib study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the CDK4 inhibitor BGB-43395 as monotherapy and in combination with other treatments in patients with HR+/HER2- metastatic breast cancer and other advanced solid tumors.

    MARIE PAULE SABLIN

  • Cancers gynécologiques
    Saint-Cloud
    E7386-J081-102_(PENT-02)
    An Open-Label Study of E7386 in Combination With Other;Anticancer Drug(s) in Subjects With Solid Tumors.

    DIANA BELLO ROUFAI